// App-Quantinova.ai

OP0230 (2021) : EFFICACY AND SAFETY OF GUSELKUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS WHO DEMONSTRATED INADEQUATE RESPONSE TO TUMOR NECROSIS FACTOR INHIBITION: WEEK 24 RESULTS OF A PHASE 3B, RANDOMIZED, CONTROLLED STUDY

Researchers

Presenter

  • L. C. Coates

Principal Investigators

  • L. Gossec

  • E. Theander

  • P. Bergmans

  • M. Neuhold

  • C. Karyekar

  • M. Shawi

  • W. Noel

  • G. Schett

  • I. Mcinnes

Medical Centers

  • Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom

  • Sorbonne Université, Department of Rheumatology, Paris, France

  • Formerly at Janssen Scientific Affairs, LLC, Solna, Sweden

  • Janssen-Cilag BV, Biostatistics, Breda, Netherlands

  • Janssen Scientific Affairs, LLC, Immunology, Brussels, Belgium

  • , Janssen Global Services, LLC, Horsham, PA, United States of America

  • University of Erlangen-Nuremberg, Department of Medicine 1, Erlangen, Germany

  • University of Glasgow, Institute of Infection Immunity and Inflammation, Glasgow, United Kingdom

Locations

  • United Kingdom

  • France

  • Sweden

  • Netherlands

  • Belgium

  • United States

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

  • Dermatology

Disease

  • Psoriatic arthritis

Biomarkers

  • N/A

Drug/Treatment

  • guselkumab (IV)

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Cross Over

  • Double Blind/Blinded

  • Controlled

Phase

  • III

Study Id's

  • N/A

Sponsors

  • Abbvie

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved